```html

Fluoroquinolone‑Associated Tendinopathy

Overview

Fluoroquinolone‑associated tendinopathy (FQ‑tendinopathy) is a drug‑induced disorder in which the tendons—most commonly the Achilles tendon—become inflamed, degenerated, or rupture after exposure to fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin, moxifloxacin). The condition can develop anywhere from a few days to several months after starting therapy.

Who it affects: While anyone taking these antibiotics is theoretically at risk, certain groups experience a markedly higher incidence:

• Adults >60 years of age
• Patients on concurrent corticosteroids
• Individuals with a history of tendon disease or sports‑related overuse injuries
• Patients with chronic kidney disease or renal failure (drug accumulation)
• Women (some studies suggest a modestly higher risk)

Prevalence: Large‑scale pharmaco‑epidemiologic studies estimate the incidence of clinically significant tendinopathy at 0.1 %–0.5 % of all fluoroquinolone courses, but the risk of Achilles tendon rupture rises to 1‑2 per 10,000 prescriptions in high‑risk groups (Mayo Clinic; CDC). The FDA added a boxed warning in 2016 highlighting this risk.

Symptoms

Symptoms may be subtle at first and can mimic ordinary muscle soreness. Prompt recognition is critical because tendon rupture often requires surgical repair.

Typical presentation

• Pain – a sudden, sharp or aching pain localized to the tendon (most often the posterior ankle/heel).
• Swelling or thickening – the tendon may feel enlarged or feel “boggy” on palpation.
• Stiffness – especially after periods of inactivity (e.g., morning stiffness).
• Reduced range of motion – difficulty pointing the foot downward (plantarflexion) or walking on tip‑toes.
• Audible or palpable “pop” – suggests a complete rupture.

Less common sites & symptoms

• Shoulder/glenohumeral tendons – pain during overhead activities.
• Patellar or quadriceps tendon – knee pain, swelling, difficulty climbing stairs.
• Flexor/extensor tendons of the hand – grip weakness, finger pain.
• Systemic signs – mild fever or malaise may accompany an inflammatory response, but are not specific.

Causes and Risk Factors

Mechanism of injury

Fluoroquinolones interfere with collagen synthesis and matrix remodeling by chelating magnesium ions, generating oxidative stress, and up‑regulating matrix metalloproteinases (MMPs). The net effect is weakened tendon fibers that are more susceptible to micro‑tears and, ultimately, rupture.

Key risk factors

1. Age ≥ 60 years – age‑related decreases in collagen turnover.
2. Corticosteroid use – synergistic inhibition of collagen production.
3. Renal insufficiency – reduced drug clearance leads to higher serum concentrations.
4. High‑impact or repetitive activity – athletes, manual laborers, or those who recently increased activity level.
5. Previous tendon pathology – scar tissue or chronic tendinitis.
6. Genetic predisposition – polymorphisms in COL1A1 and MMP genes are under investigation.

Diagnosis

Diagnosis is primarily clinical, supported by imaging when needed.

History and physical examination

• Document recent fluoroquinolone exposure (type, dose, duration).
• Ask about timing of symptom onset relative to the medication (often within 24 hours to 6 weeks).
• Assess for risk factors listed above.
• Physical exam: palpate the tendon for tenderness, swelling, and gaps; perform functional tests (e.g., Thompson test for Achilles rupture).

Imaging studies

• Ultrasound – first‑line, bedside tool to evaluate tendon thickness, tears, and blood flow.
• MRI – gold standard for detailed assessment of partial‑ vs. complete tears and surrounding soft‑tissue edema.
• X‑ray – not useful for tendon pathology but may be ordered to rule out associated bony avulsion.

Laboratory workup

Routine labs are usually normal, but a CBC, ESR, or CRP may be obtained to exclude infection when an inflammatory picture is atypical. Serum fluoroquinolone levels are not clinically indicated.

Treatment Options

Immediate steps

1. Discontinue the fluoroquinolone promptly – switch to an alternative antibiotic per culture results or clinical judgment.
2. Immobilize the affected tendon – use a splint, walking boot, or brace to limit stress.
3. Ice and elevation – 15‑20 minutes every 2‑3 hours for the first 48 hours to reduce swelling.

Pharmacologic management

• Analgesics – acetaminophen or NSAIDs (ibuprofen, naproxen) for pain control, unless contraindicated.
• Topical agents – diclofenac gel may aid superficial inflammation.
• Corticosteroid injection – generally avoided in fluoroquinolone‑related tendinopathy because steroids themselves increase rupture risk.

Rehabilitation and procedural interventions

• Physical therapy – once pain subsides, a graduated program focusing on gentle stretching, eccentric strengthening, and proprioception.
• Surgical repair – indicated for complete tendon rupture, especially the Achilles. Early repair (within 2 weeks) yields better functional outcomes.
• Platelet‑rich plasma (PRP) or autologous growth factor injections – emerging therapies; limited evidence but may accelerate healing in partial tears.

Adjunctive measures

• Correction of vitamin D deficiency (important for collagen synthesis).
• Ensuring adequate protein intake (≈1.2 g/kg/day for healing adults).
• Optimizing glycemic control in diabetics, as hyperglycemia impairs tendon repair.

Living with Fluoroquinolone‑Associated Tendinopathy

Daily management tips

• Activity modification – avoid high‑impact sports, running, or heavy lifting for at least 6 weeks after symptom onset.
• Footwear – wear supportive shoes with heel cushioning; consider orthotic inserts to reduce Achilles strain.
• Heat therapy after the acute inflammatory phase (48‑72 hours) can improve flexibility.
• Stretching routine – gentle calf stretches 3‑4 times daily, holding each stretch 30 seconds.
• Hydration & nutrition – maintain fluid balance; electrolytes (magnesium, calcium) support tendon health.
• Medication review – keep a list of all antibiotics taken; share with every prescriber to avoid repeat exposure.

Monitoring

Schedule follow‑up visits every 1‑2 weeks initially, then every 4‑6 weeks until full recovery. Use a visual analog scale (VAS) to track pain and a simple functional questionnaire (e.g., Victorian Institute of Sports Assessment‑Achilles score) to gauge progress.

Prevention

• Reserve fluoroquinolones for situations where no safer alternative exists (e.g., multi‑drug‑resistant urinary tract infections, certain gram‑negative pneumonia).
• Prescribe the shortest effective duration—most indications require ≤5 days.
• Screen for risk factors before prescribing: age, steroid use, renal function.
• Educate patients about early warning signs (tenderness, swelling) and to stop the drug immediately if they occur.
• Consider alternative agents such as trimethoprim‑sulfamethoxazole, nitrofurantoin, or beta‑lactams when appropriate.

Complications

If tendinopathy is missed or untreated, the following complications may arise:

• Complete tendon rupture – most common severe outcome; may require surgical repair and prolonged rehabilitation.
• Chronic tendinopathy – persistent pain and functional limitation lasting months to years.
• Post‑rupture joint stiffness or gait abnormalities – especially with delayed repair.
• Secondary infections – especially if a surgical site becomes colonized.
• Reduced quality of life – limitations in work, sports, or daily activities.

When to Seek Emergency Care

```